Results-Financial results for quarter and financial year ended 31 March 2026
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported standalone revenue of ₹30,068 lakhs for FY2026, up 20.7% from ₹24,910 lakhs in FY2025, meeting the 20% revenue growth threshold. Profit after tax grew modestly by 1.9% to ₹3,406 lakhs versus ₹3,344 lakhs in the prior year. The company proposed a dividend of ₹0.50 per share (25% payout) for FY2025-26, a notable improvement from zero dividend the previous year. The auditor issued an unmodified (clean) opinion with no qualifications or going concern concerns. A dispute with the Government of Meghalaya involving a step-down subsidiary has resulted in operational losses, with ₹392.20 lakhs of investments and loans under assessment. The company acquired Fetomat Wellness Private Limited in April 2025, making it a subsidiary.
Revenue growth of 20.7% indicates strong business expansion, but PAT growth of only 1.9% suggests margin pressure or increased costs. The clean audit opinion and dividend announcement are positive signals for shareholders. The disputed subsidiary amount warrants monitoring.